Cannabidiol treatment for insomnia: a three-week randomised controlled pilot trial
About this study
This study will be looking at whether a medicinal cannabinoid (CBD) product can improve sleep outcomes and general wellbeing in adults with moderate to severe insomnia. It will also examine the effect on cognition, mood and general wellbeing.
What’s involved?
Participation will involve taking an oral cannabidiol (CBD) treatment or placebo nightly for a three-week period. Participants will also complete a daily sleep-monitoring diary and treatment log.
During the trial, participants will be asked to attend Swinburne University on five separate occasions:
- one screening session for a maximum of 1.5 hours
- four check-in and compliance sessions of 45 minutes each.
Participants may be eligible if aged 18 to 45 years and presenting with moderate to severe sleeping difficulties, such as difficulty falling or staying asleep, dissatisfaction with current sleep patterns, or sleep problems interfering with daily life. Additional criteria apply.
Our research ethics and integrity
Our researchers are committed to the highest ethical, professional and scholarly standards. All our studies conform to the Australian Code for the Responsible Conduct of Research, Good Clinical Practice and the National Statement on Ethical Conduct in Human Research.
Explore more from our centre
Contact the Centre for Human Psychopharmacology
There are many ways to engage with us. If your organisation is dealing with a complex problem, get in touch to discuss how we can work together to provide solutions. Call us on +61 3 9214 4444 or email chp@swinburne.edu.au.